Immuno-Oncology | Specialty

The immuno-oncology condition center is a comprehensive resource for clinical news and expert insights on immuno-oncology. Read more at OncLive.

Adjuvant Pembrolizumab Delivers Long-Term Benefits in ccRCC at Increased Risk of Recurrence

December 5th 2025

Adjuvant pembrolizumab delivers sustained clinical benefits across ccRCC subgroups with no new long-term safety signals.

PLN-101095 Plus Pembrolizumab Displays Activity in ICI-Refractory Advanced Solid Tumors

December 4th 2025

PLN-101095 in combination with pembrolizumab led to responses in patients with ICI-refractory advanced solid tumors.

Updated Cosibelimab Label Reflects Long-Term Data in Advanced CSCC

December 2nd 2025

The prescribing information for cosibelimab in advanced cutaneous squamous cell carcinoma was updated to include long-term data from the CK-301-101 trial.

Revisit Every OncLive On Air Episode From November 2025

December 2nd 2025

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2025.

OncLive’s November Roundup of Key FDA Approvals in Oncology: 10 Decisions to Know

December 2nd 2025

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in November 2025 spanning tumor types.

Subcutaneous Pembrolizumab Approved in EU for All Adult Indications

December 1st 2025

Pembrolizumab obtained approval from the European Commission for subcutaneous administration for all adult indications.

The OncFive: Top Oncology Articles for the Week of 11/23

November 29th 2025

The FDA approved a new option in resectable gastric cancer, and a new agent is under priority review in mantle cell lymphoma.

DESTINY-Endometrial01 Will Examine T-DXd Plus Rilvegostomig or Pembrolizumab in HER2+ pMMR Endometrial Cancer

November 26th 2025

Vicky Makker, MD, discusses the DESTINY-Endometrial01 trial of T-DXd plus rilvegostomig or pembrolizumab in HER2+ pMMR endometrial cancer.

FDA Approves Perioperative Durvalumab for Resectable Gastric/GEJ Adenocarcinoma

November 25th 2025

The FDA approved durvalumab plus FLOT for the perioperative treatment of resectable gastric and gastroesophageal junction cancers.

Subcutaneous Toripalimab Plus Chemo Meets PK End Points in Recurrent/Metastatic Nonsquamous NSCLC

November 25th 2025

Subcutaneous toripalimab generated non-inferior efficacy and safety outcomes vs the IV formulation in recurrent/metastatic non squamous NSCLC.

Sacituzumab Tirumotecan Plus Pembrolizumab Improves PFS in PD-L1+ Advanced NSCLC

November 24th 2025

Sacituzumab tirumotecan plus pembrolizumab improved PFS as first-line treatment in PD-L1–positive advanced NSCLC.

The OncFive: Top Oncology Articles for the Week of 11/16

November 22nd 2025

The FDA approved 5 therapeutic options spanning lung cancer, urothelial cancer, NF1-associated PNs, and AL amyloidosis.

FDA Approves Perioperative Enfortumab Vedotin Plus Pembrolizumab for Cisplatin-Ineligible MIBC

November 21st 2025

The FDA has approved neoadjuvant/adjuvant enfortumab vedotin plus pembrolizumab for cisplatin-ineligible muscle-invasive bladder cancer.

Adjuvant Cemiplimab Cleared in EU for CSCC With High Recurrence Risk After Surgery and Radiation

November 19th 2025

Cemiplimab wins EU approval after C-POST shows DFS gains for high-risk CSCC, marking the first effective adjuvant immunotherapy option.

The OncFive: Top Oncology Articles for the Week of 11/9

November 15th 2025

The FDA has approved ziftomenib for NPM1-positive acute myeloid leukemia, has accepted a NDA for 177Lu-edotreotide for GEP-NETs, and more.

MD Anderson Experts Spotlight Key Immunotherapy Advances at 2025 SITC Annual Meeting

November 11th 2025

Researchers at The University of Texas MD Anderson Cancer Center shared insights about how the immune system can be trained to improve patient outcomes.

The OncFive: Top Oncology Articles for the Week of 11/2

November 8th 2025

The FDA clears subcutaneous daratumumab in smoldering myeloma, adds REMS guidelines for pexidartinib in TGCT, and more.

FDA Grants Orphan Drug Designation to M2T-CD33 for Acute Myeloid Leukemia

November 5th 2025

The FDA has granted orphan drug designation to M2T-CD33 for the treatment of patients with acute myeloid leukemia.

Cemiplimab Receives Reimbursement in Seven Provinces for NSCLC, Basal Cell Carcinoma

October 31st 2025

Seven provinces have agreed to reimburse cemiplimab for the treatment of patients with advanced non–small cell lung cancer and basal cell carcinoma.

OncLive’s October Roundup of Key FDA Approvals in Oncology: 4 Decisions to Know

October 31st 2025

Here is your guide to all therapeutic options that were approved by the FDA in October 2025 spanning tumor types.